ResMed Inc. (ASX:RMD)
| Market Cap | 53.70B |
| Revenue (ttm) | 7.95B +9.4% |
| Net Income | 2.17B +29.2% |
| EPS | 14.77 +29.6% |
| Shares Out | n/a |
| PE Ratio | 24.70 |
| Forward PE | 22.96 |
| Dividend | 0.34 (0.93%) |
| Ex-Dividend Date | Nov 12, 2025 |
| Volume | 758,591 |
| Average Volume | 647,376 |
| Open | 37.00 |
| Previous Close | 36.82 |
| Day's Range | 36.20 - 37.00 |
| 52-Week Range | 32.04 - 45.25 |
| Beta | 0.88 |
| RSI | 40.75 |
| Earnings Date | Jan 29, 2026 |
About ResMed
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring... [Read more]
Financial Performance
In fiscal year 2025, ResMed's revenue was $5.15 billion, an increase of 9.84% compared to the previous year's $4.69 billion. Earnings were $1.40 billion, an increase of 37.20%.
Financial numbers in USD Financial StatementsNews
Stay Ahead of the Game With ResMed (RMD) Q2 Earnings: Wall Street's Insights on Key Metrics
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart...
PDS Planning, Inc Sells 750 Shares of ResMed Inc (RMD)
PDS Planning, Inc Sells 750 Shares of ResMed Inc (RMD)
Reyes Financial Architecture, Inc. Sells 109 Shares of ResMed Inc (RMD)
Reyes Financial Architecture, Inc. Sells 109 Shares of ResMed Inc (RMD)
Annex Advisory Services, LLC Sells 746 Shares of ResMed Inc (RMD)
Annex Advisory Services, LLC Sells 746 Shares of ResMed Inc (RMD)
Goldman Sachs Strategic Factor Allocation Fund Buys 2,482 Shares of ResMed Inc (RMD)
Goldman Sachs Strategic Factor Allocation Fund Buys 2,482 Shares of ResMed Inc (RMD)
Pinnacle Bancorp, Inc. Sells 225 Shares of ResMed Inc (RMD)
Pinnacle Bancorp, Inc. Sells 225 Shares of ResMed Inc (RMD)
Addenda Capital Inc. Sells 1,077 Shares of ResMed Inc (RMD)
Addenda Capital Inc. Sells 1,077 Shares of ResMed Inc (RMD)
Weaver Capital Management LLC Sells 277 Shares of ResMed Inc (RMD)
Weaver Capital Management LLC Sells 277 Shares of ResMed Inc (RMD)
GraniteShares Advisors LLC Sells 2,336 Shares of ResMed Inc (RMD)
GraniteShares Advisors LLC Sells 2,336 Shares of ResMed Inc (RMD)
Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Resmed Inc at JPMorgan Healthcare Conference Transcript
Resmed Inc at JPMorgan Healthcare Conference Transcript
ResMed Inc. (RMD) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD)
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RMD)
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026
SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, ...
Is This the Right Time to Add Resmed Stock to Your Portfolio?
RMD is seeing rising device demand, expanding international sales and strong liquidity, but macroeconomic pressures could weigh on future performance.
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD)
Insider Sell: Brett Sandercock Sells 1,000 Shares of ResMed Inc (RMD)
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Buy These 5 Low-Leverage Stocks Amid a Reversal of Santa Claus Rally
A stalled Santa Claus rally has investors rotating to stability, spotlighting low-leverage names like Resmed that may hold up better amid tech-led volatility.
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
Why ResMed (RMD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Have an RMD Coming Your Way This December? 3 Ways to Make the Most of It.
It's important that you put that money to good use.
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present ...
Stifel Lowers Price Target for ResMed (RMD) to $260, Maintains Hold Rating | RMD Stock News
Stifel Lowers Price Target for ResMed (RMD) to $260, Maintains Hold Rating | RMD Stock News